The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 10: 1344 - 1350

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.10.003

Basic Research

Expression of S100A7A in gastric cancer and its effect on proliferation and metastasis

  • Wushuang XIAO ,
  • Linjie HONG ,
  • Zhen YU ,
  • Ping YANG ,
  • Jieming ZHANG ,
  • Siyang PENG ,
  • Xiangyang WEI ,
  • Yidong CHEN ,
  • Side LIU ,
  • Jide. WANG
Expand
  • Department of Gastroenterology，Nanfang Hospital，Southern Medical University，Guangzhou 510515，China

Received date: 2023-10-25

  Online published: 2024-05-21

Fold

Abstract

Objective The objective of this study is to examine the expression level of the S100A7A protein in both gastric cancer tissues and cells， as well as to evaluate its impact on the malignant phenotype of gastric cancer （GC） cells. Methods Immunohistochemical assay was used to detect the expression characteristics of S100A7A in 21 gastric cancer tissues and their corresponding paracancerous tissues， as well as to investigate its correlation with gastric cancer clinicopathological factors. Gastric cancer cells were genetically modified to overexpress S100A7A through plasmid transfection. Subsequently， the impact of S100A7A on the proliferation， migration， and invasion capacities of gastric cancer cells was assessed using cell proliferation assays （EdU assay and plate cloning assay） as well as cell migration and invasion assays （Transwell assay and scratch assay）. Results The expression of S100A7A protein was higher in GC tissues than in paracancerous tissues； Overexpression of S100A7A may increase gastric cancer cell proliferation， migration， and invasion. Conclusion S100A7A is a possible oncogene in GC and is predicted to serve as a new diagnostic and therapeutic target for the disease.

Key words： gastric cancer; S100A7A; proliferation; migration; invasion

Cite this article

Wushuang XIAO , Linjie HONG , Zhen YU , Ping YANG , Jieming ZHANG , Siyang PENG , Xiangyang WEI , Yidong CHEN , Side LIU , Jide. WANG . Expression of S100A7A in gastric cancer and its effect on proliferation and metastasis[J]. The Journal of Practical Medicine, 2024 , 40(10) : 1344 -1350 . DOI: 10.3969/j.issn.1006-5725.2024.10.003

References

1 SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin，2021，71（3）：209-249. doi:10.3322/caac.21660
2 YANG L， YING X， LIU S， et al. Gastric cancer： Epidemiology， risk factors and prevention strategies［J］. Chin J Cancer Res，2020，32（6）：695-704. doi:10.21147/j.issn.1000-9604.2020.06.03
3 GBD 2017 STOMACH CANCER COLLABORATORS. The global， regional， and national burden of stomach cancer in 195 countries， 1990-2017： a systematic analysis for the Global Burden of Disease study 2017［J］. Lancet Gastroenterol Hepatol，2020，5（1）：42-54.
4 QIU H， CAO S， XU R. Cancer incidence， mortality， and burden in China： a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020［J］. Cancer Commun （Lond）， 2021，41（10）：1037-1048. doi:10.1002/cac2.12197
5 SITARZ R， SKIERUCHA M， MIELKO J， et al. Gastric cancer： epidemiology， prevention， classification， and treatment［J］. Cancer Manag Res， 2018，10：239-248. doi:10.2147/cmar.s149619
6 DONATO R， CANNON B R， SORCI G， et al. Functions of S100 proteins［J］. Curr Mol Med， 2013，13（1）：24-57. doi:10.2174/15665240130104
7 BRESNICK A R， WEBER D J， ZIMMER D B. S100 proteins in cancer［J］. Nat Rev Cancer， 2015，15（2）：96-109. doi:10.1038/nrc3893
8 BüCHAU A S， HASSAN M， KUKOVA G， et al. S100A15， an antimicrobial protein of the skin： regulation by E. coli through Toll-like receptor 4［J］. J Invest Dermatol， 2007，127（11）：2596-2604. doi:10.1038/sj.jid.5700946
9 ZHANG L， BU Z， SHEN J， et al. A novel circular RNA （hsa_circ_0000370） increases cell viability and inhibits apoptosis of FLT3-ITD-positive acute myeloid leukemia cells by regulating miR-1299 and S100A7A［J］. Biomed Pharmacother， 2020，122：109619. doi:10.1016/j.biopha.2019.109619
10 O'CONNOR A， MCNAMARA D， O'MORáIN C A. Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer［J］. Cochrane Database Syst Rev， 2013（9）：D9322.
11 PIMENTEL-NUNES P， LIB?NIO D， MARCOS-PINTO R， et al. Management of epithelial precancerous conditions and lesions in the stomach （MAPS Ⅱ）： European Society of Gastrointestinal Endoscopy （ESGE）， European Helicobacter and Microbiota Study Group （EHMSG）， European Society of Pathology （ESP）， and Sociedade Portuguesa de Endoscopia Digestiva （SPED） guideline update 2019［J］. Endoscopy， 2019，51（4）：365-388. doi:10.1055/a-0859-1883
12 LORDICK F， CARNEIRO F， CASCINU S， et al. Gastric cancer： ESMO Clinical Practice Guideline for diagnosis， treatment and follow-up［J］. Ann Oncol， 2022，33（10）：1005-1020. doi:10.1016/j.annonc.2022.07.004
13 NAKAMURA Y， KAWAZOE A， LORDICK F， et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers： an emerging paradigm［J］. Nat Rev Clin Oncol， 2021，18（8）：473-487. doi:10.1038/s41571-021-00492-2
14 YAMAGUCHI K， BANG Y J， IWASA S， et al. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma： Exploratory Cohort Results in a Phase Ⅱ Trial［J］. J Clin Oncol， 2023，41（4）：816-825. doi:10.1200/jco.22.00575
15 YANG W J， ZHAO H P， YU Y， et al. Updates on global epidemiology， risk and prognostic factors of gastric cancer［J］. World J Gastroenterol， 2023，29（16）：2452-2468. doi:10.3748/wjg.v29.i16.2452
16 THRIFT A P， El-Serag H B. Burden of Gastric Cancer［J］. Clin Gastroenterol Hepatol，2020，18（3）：534-542. doi:10.1016/j.cgh.2019.07.045
17 GONZALEZ L L， GARRIE K， TURNER M D. Role of S100 proteins in health and disease［J］. Biochim Biophys Acta Mol Cell Res， 2020，1867（6）：118677. doi:10.1016/j.bbamcr.2020.118677
18 BRESNICK A R. S100 proteins as therapeutic targets［J］. Biophys Rev， 2018，10（6）：1617-1629. doi:10.1007/s12551-018-0471-y
19 ALLG?WER C， KRETZ A L， VON KARSTEDT S， et al. Friend or Foe： S100 Proteins in Cancer［J］. Cancers （Basel）， 2020，12（8）：2037. doi:10.3390/cancers12082037
20 LIN Z， DENG L， JI J， et al. S100A4 hypomethylation affects epithelial-mesenchymal transition partially induced by LMP2A in nasopharyngeal carcinoma［J］. Mol Carcinog， 2016，55（10）：1467-1476. doi:10.1002/mc.22389
21 LIU J， GUO Y， FU S， et al. Hypomethylation-induced expression of S100A4 increases the invasiveness of laryngeal squamous cell carcinoma［J］. Oncol Rep， 2010，23（4）：1101-1107. doi:10.3892/or_00000738
22 XIE R， LOOSE D S， SHIPLEY G L， et al. Hypomethylation-induced expression of S100A4 in endometrial carcinoma［J］. Mod Pathol， 2007，20（10）：1045-1054. doi:10.1038/modpathol.3800940
23 BATYCKA-BARAN A， HATTINGER E， ZWICKER S， et al. Leukocyte-derived koebnerisin （S100A15） and psoriasin （S100A7） are systemic mediators of inflammation in psoriasis［J］. J Dermatol Sci， 2015，79（3）：214-221. doi:10.1016/j.jdermsci.2015.05.007
24 KURPET K， CHWATKO G. S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases［J］. Molecules， 2022，27（19）：6640. doi:10.3390/molecules27196640
25 JI Y Z， LIU S R. Koebner phenomenon leading to the formation of new psoriatic lesions： evidences and mechanisms［J］. Biosci Rep， 2019，39（12）：BSR20193266. doi:10.1042/bsr20193266
26 KO J H， SON M Y， ZHOU Q， et al. TREX2 Exonuclease Causes Spontaneous Mutations and Stress-Induced Replication Fork Defects in Cells Expressing RAD51（K133A）［J］. Cell Rep， 2020，33（12）：108543. doi:10.1016/j.celrep.2020.108543
27 HU L， KIM T M， SON M Y， et al. Two replication fork maintenance pathways fuse inverted repeats to rearrange chromosomes［J］. Nature， 2013，501（7468）：569-572. doi:10.1038/nature12500
28 PARUCHURI V， PRASAD A， MCHUGH K， et al. S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation［J］. PLoS One， 2008，3（3）：e1741. doi:10.1371/journal.pone.0001741
29 SNEH A， DEOL Y S， GANJU A， et al. Differential role of psoriasin （S100A7） in estrogen receptor α positive and negative breast cancer cells occur through actin remodeling［J］. Breast Cancer Res Treat， 2013，138（3）：727-739. doi:10.1007/s10549-013-2491-4
30 TAKAHATA M， INOUE Y， TSUDA H， et al. SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells［J］. J Biol Chem， 2009，284（5）：3334-3344. doi:10.1074/jbc.m808989200
31 LI R， GU Z， ZHANG X， et al. RNF115 deletion inhibits autophagosome maturation and growth of gastric cancer［J］. Cell Death Dis， 2020，11（9）：810. doi:10.1038/s41419-020-03011-w
32 ZHONG B， WANG K， XU H， et al. Silencing Formin-like 2 inhibits growth and metastasis of gastric cancer cells through suppressing internalization of integrins［J］. Cancer Cell Int， 2018，18：79. doi:10.1186/s12935-018-0576-1
33 K?LLBERG E， VOGL T， LIBERG D， et al. S100A9 interaction with TLR4 promotes tumor growth［J］. PLoS One， 2012，7（3）：e34207. doi:10.1371/journal.pone.0034207
34 DHAR A， MALLICK S， GHOSH P， et al. Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide［J］. Biopolymers， 2014，102（4）：344-358. doi:10.1002/bip.22505
Options
Outlines

/

〈 〉